Recruiting studies: Melanoma Stage Iii Or Iv

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresecta
Phase 2 · 1 location(s) · Philogen S.p.A. · NCT06284590 A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497 BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196 A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Met
Phase 1/Phase 2 · 11 location(s) · Iovance Biotherapeutics, Inc. · NCT05361174 Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Phase N/A · 59 location(s) · Pierre Fabre Pharma GmbH · NCT04045691 Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06295159 Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma
NA · 5 location(s) · Azienda Ospedaliera di Perugia · NCT07050940 Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metasta
Phase 1/Phase 2 · 26 location(s) · National Cancer Institute (NCI) · NCT05896839 A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Phase 2/Phase 3 · 9 location(s) · Linnaeus Therapeutics, Inc. · NCT06624644 A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melan
Phase 3 · 110 location(s) · Regeneron Pharmaceuticals · NCT06246916 Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801 Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untrea
Phase 3 · 81 location(s) · Iovance Biotherapeutics, Inc. · NCT05727904 MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Phase 1/Phase 2 · 13 location(s) · Perspective Therapeutics · NCT05655312 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086 Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary
Phase N/A · 27 location(s) · Assistance Publique - Hôpitaux de Paris · NCT02828202 IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04562129 To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
Phase 1 · 2 location(s) · Inge Marie Svane · NCT06204991 Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
NA · 1 location(s) · Erasmus Medical Center · NCT05652673 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024 Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Res
Phase N/A · 3 location(s) · Pamgene International B.V. · NCT06784778 Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unr
Phase 2 · 4 location(s) · NYU Langone Health · NCT05428007 Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.